BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 17, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Laninamivir: Phase II/III data

A double-blind, Japanese Phase II/III trial in about 180 patients <=9 years old with influenza A or B virus infection showed that both doses of laninamivir met the primary endpoint of non-inferiority to Tamiflu oseltamivir in time...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >